Back to All

Diaceutics co-authors pivotal paper outlining a roadmap for the potential use of innovative multicancer early detection testing

31 March, 2022

Featured

As a thought leader in Precision Medicine, Diaceutics CEO Peter Keeling has contributed to a pivotal paper outlining a roadmap for the potential use of innovative multicancer early detection (MCED) testing. The paper, published in Cancer on 15th February 2022, is the result of a two-year international collaboration led by  global thought leaders. 

“We believe the shift towards MCED, alongside single organ testing, fits our mission at Diaceutics to build an integrative platform (DXRX) focused on accelerating the adoption of impactful patient testing. Whilst the bar for introducing early cancer detection is high, we believe that addressing the “now recognized hurdles” at the front line, with practical multi-stakeholder collaborations, continues to be the right way to optimize the introduction of such disruptive test paradigms. We are delighted to have been part of this international body of experts and to be able to shape future thinking around the diffusion of this important paradigm shift.  We believe our DXRX platform can play a pivotal supporting role,” commented Peter Keeling.

Read the full paper here: Industry engagement: Accelerating discovery, application, and adoption through industry partnerships - Peralta - 2022 - Cancer - Wiley Online Library





About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny